Over the last two decades, the cannabis landscape in the U.S. has changed considerably. Legalization, product potency and commercialization have increased while perceived risk has declined. In this context, national increases in cannabis use and cannabis use disorder will be reviewed, including particular subgroups in which the increases have been disproportionately large, e.g., individuals with pain and with psychiatric disorders, including psychosis.
Dr. Hasin is Professor of Epidemiology at Columbia University. She directs the NIDA T32 Substance Abuse Epidemiology Training Program in the Department of Epidemiology in Mailman, and also directs the Substance Dependence Research Group at New York State Psychiatric Institute. Dr. Hasin conducts research on drug and alcohol use and substance use disorders in the general population and in specialized vulnerable groups. She has published over 500 papers. Her studies are funded by the National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), and other organizations. She currently leads three NIH-funded studies, as well as studies funded by other sources, and sponsors and mentors K and other awards of junior scientists. Dr. Hasin's current studies include the relationship of state cannabis laws to use of cannabis and other substances; time trends in drug and alcohol disorders in the U.S.; and the validity of DSM-5 definitions of substance and psychiatric disorders in national and clinical populations. Dr. Hasin has participated in World Health Organization studies, served on the National Advisory Council to NIAAA, and been a member of the American Psychiatric Association's DSM-5 Substance Use Disorders Workgroup. She is past president of the American Psychopathological Association and is currently President of the College on Problems of Drug Dependence.
